Abstract Breast carcinoma (BC) corresponds to 23 % of all cancers in women, with 1.38 million new cases and 460,000 deaths worldwide annually. Despite the significant advances in the identification of molecular markers and different modalities of treatment for primary BC, the ability to predict its metastatic behavior is still limited. The purpose of this study was to identify novel molecular markers associated with distinct clinical outcomes in a Brazilian cohort of BC patients. We generated global gene expression profiles using tumor samples from 24 patients with invasive ductal BC who were followed for at least 5 years, including a group of 15 patients with favorable outcomes and another with nine patients who developed metastasis. We identified a set of 58 differentially expressed genes (p ≤ 0.01) between the two groups. The prognostic value of this metastasis signature was corroborated by its ability to stratify independent BC patient datasets according to disease-free survival and overall survival. The upregulation of B3GNT7, PPM1D, TNKS2, PHB, and GTSE1 in patients with poor outcomes was confirmed by quantitative reverse transcription polymerase chain reaction (RT-qPCR) in an independent sample of patients with BC (47 with good outcomes and eight that presented metastasis). The expression of BCL2-associated agonist of cell death (BAD) protein was determined in 1276 BC tissue samples by immunohistochemistry and was consistent with the reduced BAD mRNA expression levels in metastatic cases, as observed in the oligoarray data. These findings point to novel prognostic markers that can distinguish breast carcinomas with metastatic potential from those with favorable outcomes. Silvia R. Rogatto and Eduardo M. Reis contributed equally to this study.
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Introduction
Breast cancer (BC) is a complex and heterogeneous disease, with distinct clinical presentations in different patient and ethnic populations. Even patients affected by tumors with similar histomorphological appearances may present divergent clinical courses [1, 2] . During the last few decades, several clinical and pathological indicators, such as histological grade, tumor size, and lymph node involvement, have been used for prognostic prediction in breast cancer patients [3] . In addition, the predictive and prognostic markers applied to the management of patients include the estrogen (ESR1) and progesterone receptor (PR) statuses and human epidermal growth factor receptor 2 (Her2) amplification and/or overexpression. The clinico-pathological risk assessment is routinely based on these factors and is used to guide decisions on adjuvant systemic treatment [4] . Despite the improvements in risk stratification, the current prognostic factors show moderate accuracy in classifying breast tumors according to their clinical behaviors. It is still a clinical challenge to identify the patients who are at a low risk of relapse and have been submitted to overtreatment after optimal locoregional treatment as well as those who are at a high risk of relapse and would benefit from a more aggressive adjuvant systemic therapy and closer followup.
New biomarker development is required to assist clinicians in BC detection and diagnosis, risk stratification, disease subtyping, prediction of treatment responses, and surveillance, allowing personalized cancer management. The integration between novel biomarkers and routinely tested clinico-pathological features, such as hormone receptor (HR) and Her2 statuses, may guide clinicians in their systemic therapy decisions regarding both primary and metastatic tumors [5] [6] [7] [8] .
In recent years, gene expression prognostic tests for BC that are better predictors of clinical outcomes than traditional pathological factors have been developed [9] [10] [11] [12] . One of the first commercially available and US Food and Drug Administration (FDA)-approved signatures was the 70-gene MammaPrint assay® (Agendia Inc.). MammaPrint is among the most validated multigene prognostic signatures and is widely used to stratify lymph node-negative patients as having low or high risks of distant metastases at 5 years from surgery [13] . The 21-gene Oncotype Dx® assay (Genomic Health Inc.) has also been extensively used to estimate the risk of relapse in estrogen receptor (ER)+, node-negative BC, and their chemosensitivities. A common feature between both signatures is the ability to better estimate the risk of recurrence compared to conventional clinical criteria, such as the St.
Gallen and NIH consensus criteria or web-based decision tools (e.g., Adjuvant! Online; https://www.adjuvantonline. com). This improvement in risk estimation can help to reduce the number of over treated women, which emphasizes the advantage of these gene signatures over the clinical guidelines [14, 15] . Other multigene expression-based prognostic tests interrogating different sets of genes have been made commercially available more recently, with comparable prognostic performances in BC [8] . PAM50, which is based on a 50-gene set, generates a numerical score (risk of recurrence, or ROR) that, along with the clinical features, estimates the risk of relapse at 10 years in postmenopausal women with stage I/II node-negative or stage II node-positive (one to three positive lymph nodes) and HR-positive BC [16] . The 97-gene MapQuant Dx® (Ipsogen-Qiagen) has been used to resolve intermediate grade 2 BC tumors into those with a good prognosis, grade 1-like behavior, or more aggressive grade 3-like tumors [17] . Finally, the breast cancer index (BCI; Biotheranostics, Inc.) combines the information from the expression ratio of two estrogen-regulated genes (HOXB13 :IL17BR) with the expression profile of five other genes known as the molecular grade index (MGI) to estimate the individualized risk of the late distant recurrence of breast cancer [18] .
These so-called first generation multigene prognostic signatures [19] show little overlap in their gene lists, which indicates that the results from the studies are unstable [20, 21] . In fact, a single dataset may generate several different signatures with clinically relevant subgroups of breast cancer [22] . On the other hand, comparative studies and meta-analyses have demonstrated that BC prognostic gene signatures tend to have similar performances and show relatively good concordance with their prognostic ability to identify patients with worse prognoses [23] [24] [25] [26] [27] and could provide a refined estimate of disease-free survival, with added value beyond the current clinical indicators [28] . Despite their demonstrated efficacy, the lack of consensus and low overlap across the genes identified in these studies indicate that the potential for identifying novel genes and expression signatures that are correlated with patient outcomes in BC has not been fully exploited.
To our knowledge, there are no descriptive studies of the molecular signatures of breast carcinomas from Brazilian patients. Brazilians form one of the most heterogeneous populations in the world, as a result of five centuries of interethnic crosses between people from three continents. For this reason, the molecular signatures of breast carcinomas from Brazilian patients may lead to the identification of new molecular markers that are common among several ethnicities. Thus, the purpose of this study was to identify new molecular markers of BC that are common in the Brazilian population and determine whether these genes can predict the patients' clinical outcomes. Global gene expression profiles generated from 24 locally invasive ductal breast carcinoma samples from patients staged M0 at diagnosis with subsequent metastasis (n = 9) and patients who remained disease-free at a minimum follow-up of 60 months (n = 15) were used to identify a 58-gene set associated with patient outcome. The robustness of this signature to predict disease outcome (disease-free survival and overall survival) was corroborated by the analysis of publicly available BC gene expression datasets. Quantitative reverse transcription polymerase chain reaction (RT-qPCR) was used to confirm the differential expression of a selected set of candidate markers in an independent validation set of 55 new cases (comprising 47 patients with 5-year metastasis-free BC and eight patients with metastatic disease). Furthermore, the potential of the BCL-2-associated agonist of cell death promoter (BAD) protein as a new prognostic biomarker of BC was validated using a tissue microarray comprising 1276 BC samples.
Materials and methods

Patients
The study included 79 female patients with infiltrating ductal breast cancer, with a mean age of 58 ± 16 years (ranged from 24 to 94 years). The mean follow-up after the surgery was 87.5 ± 17.4 months (ranged from 57 to 117 months). The criteria for patient inclusion were no previous or concomitant diagnosis of any cancer or metastasis at diagnosis. The patients were treated with segmental resection or mastectomy, including dissection of the axillary lymph nodes, followed by radiotherapy and adjuvant systemic therapy, if indicated. None of them received radiotherapy or chemotherapy prior to surgery. After surgery, 64 patients (81 %) received radiotherapy and 43 (54 %) were treated with tamoxifen (20 mg/day) for 60 months at the end of chemotherapy. All patients who developed metastasis (17 cases) presented operable stage II and III breast cancers, with larger tumors (>2 cm) that were often poorly differentiated, and all except one showed positive axillary lymph nodes. Of this group, the majority (13 patients) received chemotherapy following surgery. Of the 14 patients with an ER-positive status, the majority (11 patients) were also treated with hormone therapy.
Fresh tissue samples were macro-dissected (>80 % of tumor cells) and used for RNA isolation and the subsequent gene expression analysis. Thirty-eight cases were used for the global gene expression analysis using oligoarrays, and 55 cases were used for RT-qPCR analysis of the candidate genes. In addition, tumor tissue samples from 1276 ductal breast carcinomas were evaluated for protein expression by immunohistochemistry. The samples were obtained from Amaral Carvalho Hospital, Jau (SP, Brazil), and AC Camargo Cancer Center (SP-Brazil). Written informed consent was obtained from all patients during the collection period, and the study was reviewed and approved by the Ethics Committees from both institutions (CEP FHAC 340/04 and CEP ACCC 1155/08).
Analysis design
The expression profiles from tumor samples obtained from 38 patients were used to identify the molecular signatures that were correlated with the Her2 and Ki67 expression statuses, two of the currently used prognostic markers. The detailed clinico-pathological data from these patients is shown in Supplementary Table 1 . A subset of 24 cases (test set) with known outcomes was used to identify a gene expression signature associated with the development of metastasis. The ability of the Bmetastasis signature^to stratify patients based on the time to develop metastasis was compared to a combined prognostic score based on traditional clinico-pathological criteria that assigned patients to a Bgood outcome^group comprised of 15 patients who remained free of disease at least 5 years after surgery. Nine patients who developed metastasis were assigned to the Bpoor outcome^group. The criteria used to assign a patient to the good outcome group were the presence of at least five of the following parameters: (i) tumor clinical stage I or IIA; (ii) tumor size less than 2 cm; (iii) histopathological grade I or II; (iv) negative axillary lymph node status or less than four nodes compromised; (v) ERpositive (scores 2+/3+) in the immunohistochemistry assay; (vi) Her2-negative or (1+) in the immunohistochemistry assay; and (vii) low proliferation index (<25 % of cells with Ki67-positive staining). To verify if the development of metastasis in this sample set could be explained by the traditional clinico-pathological factors alone, the association between these variables was evaluated using Fisher's exact test (GraphPad Prism Statistical Software version 5.0, San Diego, CA, USA) and statistical significance was designated at p ≤ 0.05 (Supplementary Table 2 ). The histological grade, proliferation index, and adjuvant chemotherapy were individual characteristics that were statistically related to the development of metastasis in the group of patients analyzed.
The independent validation set (55 samples) included 47 samples from patients with good outcomes and eight samples from patients with poor outcomes. A summary of the clinicopathological data from the 79 patients with a known follow-up that comprised the samples used in the gene expression experiments (test + validation set) is shown in Supplementary  Table 3 . Information on the additional 1276 cases used in tissue microarray validation experiments is provided in Supplementary Table 4 .
RNA isolation and global gene expression analysis
The total RNA was extracted using the RNeasy mini Kit (Qiagen GmbH, Germany). RNA samples were treated with DNAse I Amplification Grade (Life Technologies, Rockville, MD, USA) according to the manufacturer's recommendations. The concentrations and integrity of the RNA samples were assessed using the ND-1000 spectrophotometer (NanoDrop Inc., Thermo Scientific, Wilmington, DE, USA) and Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA), respectively. Only samples with an RNA integrity number (RIN) ≥ 7 were considered for further analysis. The gene expression profiles were collected using Whole Human Genome CodeLink bioarrays (GE Healthcare Buckinghamshire, UK), which interrogated approximately 54,000 transcripts (GEO accession GPL11010). In brief, first-strand complementary DNAs (cDNAs) were produced using 2 μg of total RNA from each sample, Superscript II reverse transcriptase, and a T7-poly-dT primer. Secondstrand cDNAs were produced using RNase H and E. coli DNA polymerase I. The double-stranded cDNAs were column purified (QIAquick, Qiagen), and biotin-labeled complementary RNA (cRNA) targets were generated in an in vitro transcription reaction using T7 RNA polymerase and biotin-11-UTP (Perkin Elmer, Foster City, CA, USA). Fragmented cRNAs from each sample were hybridized to CodeLink microarrays overnight at 37°C in a shaking incubator at 300 rpm. After post-hybridization washes, the hybridized targets were revealed by incubating the arrays with a Cy5-streptavidin conjugate. All reagents used for the synthesis and fragmentation of the cRNAs were provided in the CodeLink expression assay kit (GE Healthcare). The signals of the Cy5-dye from the hybridized targets were detected with an arrayWoRx Biochip Reader (Applied Precision LLC, Issaquah, WA, USA). CodeLink Expression Analysis software (GE Healthcare) was used to extract the backgroundsubtracted spot intensities from the microarray images. A sub set of 23,566 probes that showed valid measurements in at least 60 % of the samples was further analyzed. The intensity data were normalized across samples using the quantile method [29] . Raw and normalized expression measurements are deposited at Gene Expression Omnibus (GEO) under accession number GSE73383.
A signal-to-noise ratio (SNR) statistical test [30] was used to identify gene expression signatures that were correlated with the pathological and clinical parameters of the samples. The statistical significance of the differentially expressed genes (p values) was ascertained by bootstrapping (1000 random permutations). The expression profiles of transcripts selected in each analysis were clustered hierarchically (UPGMA with Euclidean distance) and visualized using the Spotfire Decision Site software (TIBCO Spotfire, Somerville, MA, USA). The robustness of the gene expression signature of metastasis was evaluated by leave-one-out resampling [11] , considering a p ≤ 0.01 cutoff.
Reverse transcription quantitative polymerase chain reaction
Real-time quantitative RT-qPCR amplifications for a subset of genes selected from the metastasis signature (B3GNT7, PPM1D, TNKS2, PHB, and GTSE1 genes) were performed in duplicate on an ABI Prism 7000 Sequence Detection System (Applied Biosystems, Foster City, CA, USA) using Power SYBR Green I reagent (Applied Biosystems). These genes were chosen by their importance in cell proliferation or their association with biological processes related to metastasis. The primers shown in Supplementary Table 5 were designed using the Primer Express software (v3.0; Applied Biosystems). The standard curves of the targets and reference genes showed similar amplification efficiencies (>90 %). The qPCR amplification data were analyzed using the Sequence Detection System software (v1.0; Applied Biosystems). Only the replicates with low variability (i.e., Δ cycle quantification <0.5) were considered for further analyses. GAPDH was selected as the reference gene [31] . The relative expression levels of the target genes were calculated using the ΔCt method [32] .
The normalized expression levels of the target genes in the tumor samples were represented as fold changes relative to their abundance in a pool of non-tumor breast tissues (relative quantification, RQ) and were calculated as follows: 2
. The RT-qPCR results were statistically analyzed using GraphPad InStat software (version 3.00). The Mann-Whitney test was used to ascertain the statistical significance of the expression levels evaluated by RT-qPCR. The correlation between the oligoarray and RT-qPCR data was evaluated using Spearman's correlation test. For this analysis, the raw expression values estimated by each of the two methodologies were used, and the statistical significance was ascertained using a p < 0.05 threshold.
In silico validation and functional analysis of the metastasis signature
The individual abilities of the genes present in the metastasis signature to classify patients according to their disease outcomes (presence/absence of metastasis) were evaluated by receiver operating characteristic (ROC) curves using GraphPad Prism 7 software (GraphPad Software, Inc.). For each gene, the ability to correctly identify disease-free vs. metastatic patients was evaluated by calculating the area under the ROC curve (AUC) using a non-parametric method. The ability of the 58 signatures to predict patient outcomes as a multigene biomarker was tested using SurvExpress, a webbased tool that provides survival analysis and risk assessment of publicly available cancer datasets [33] . Briefly, the tool applies the Cox proportional hazard regression model to generate risk scores (also called prognostic indexes) that relate patient survival (disease-free or overall survival) to the expression of a given gene list. The high-and low-risk patient groups were generated by splitting the samples at the median after ranking them by their risk scores. The log-rank test was used to ascertain the statistical significance of the difference between the survival curves.
Ingenuity Pathway Analysis (IPA v8.0, Ingenuity® Systems, Redwood City, CA, USA; http://www.ingenuity. com) was used to identify the enriched pathways and biological interaction networks of the differentially expressed genes identified in the oligoarray analysis. Fischer's exact test was applied to identify the significant networks and pathways that were represented within the respective gene sets. In parallel, we searched for significantly enriched pathways among the metastasis signature with the software KOBAS 2.0 [34] , which incorporates knowledge across 1327 species from five pathway databases (KEGG PATHWAY, PID, BioCyc, Reactome, and PANTHER) and five human disease databases (OMIM, KEGG DISEASE, FunDO, GAD, and NHGRI GWAS Catalog). Only pathways identified simultaneously by IPA and KOBAS with a p ≤ 0.05 were considered for further interpretation (Table 1) .
Protein expression by immunohistochemistry using tissue microarrays
Tissue microarrays (TMAs) with core biopsies from 1276 ductal breast carcinomas were assembled as previously described using a Manual Tissue Microarrayer (Beecher Instruments®, Silver Springs, USA) [35] . Tissue cores with a dimension of 1.0 mm were punched from each specimen and arrayed in quadruplicate on recipient paraffin blocks. Paraffinembedded breast tumor samples were sectioned (3 μm) and mounted on silane-coated glass slides for hematoxylin-eosin (HE) staining and immunohistochemistry (IHC).
IHC was performed using the anti-BAD (clone Y208, Epitomics diluted in 1:1500, antigen retrieval in EDTA/Tris, pH 9.0) primary antibody and secondary antibodies (Advanced TM HRP Link, Dako Cytomation, K0690, Denmark). Positive (BAD, prostate tissue) and two negative controls (omitting the primary antibody and replacing the primary antibody with normal rabbit serum) were assessed by IHC. BAD expression in each sample core was scored as positive or negative following a visual inspection of the cytoplasmic immunostaining. The final scores (median of the four cores) were obtained based on the immunostaining intensity in the cytoplasm and were denominated as Bnegative/weak( score 0-1) or Bpositive^(score 2-3). A chi-square test was applied to determine the association strength between the categorical variables (p < 0.05). Univariate Kaplan-Meier (KM) survival curves were calculated for systemic diseasefree survival (SDFS) and cancer-specific survival (CSS) probabilities by considering a minimum 60-month follow-up after surgery. The log-rank test was used to assess the statistical significance of the KM curves. IHC analysis was blinded to the outcomes and clinical aspects of each tumor specimen. A minimum 5-year follow-up after surgery was used for both SDFS and CSS. Multivariate analysis was performed using the Cox proportional hazard model. The statistical analyses were performed using MedCalc v. 15.11.0 (MedCalc Software, Belgium), GraphPad Prism3 (San Diego, CA, USA), and SPSS version 15.0 (SPSS, Chicago, IL, USA).
Results
Gene expression signatures associated with metastatic ductal breast carcinoma First, the global gene expression profiles were evaluated in 38 BC samples to identify gene signatures that were correlated with the commonly used prognostic markers of breast cancer outcome (expression of ESR1/PR, Ki67, and Her2), with the aim of distinguishing patients who developed metastasis from those that remained disease-free. Using a two-class supervised analysis based on a SNR with permutation [30] , we identified statistically significant gene expression signatures that were correlated with the expression of estrogen/progesterone receptors (p ≤ 0.005), Ki67 (p ≤ 0.001), or Her2 (p ≤ 0.001). Although these expression signatures accurately discriminate samples based on each prognostic marker, they are poor estimators of risk of metastatic progression in patients with invasive BC (Supplementary Figure 1) .
Next, we sought to identify a gene expression signature that was correlated with disease outcome, i.e., the development of metastasis. For this analysis, we only included samples from the 15 patients with a good prognosis that remained free of disease for at the least 5 years. SNR with permutation was used and identified 200 full-length or partial transcript (EST) sequences that were differentially expressed (p ≤ 0.01) between the samples from patients who developed metastasis (nine cases) and those from patients with a good prognosis that remained disease-free (15 cases). Hierarchical clustering of this transcript set correctly grouped the samples according to their metastatic outcome, with the exception of one sample (Supplementary Figure 2 and Supplementary Table 6 ).
To identify the most robust markers of metastasis, a Bleaveone-out^(LOO) cross-validation procedure [11] reduced the initial 200-gene signature to a 58-transcript set comprising sequences that are present in all LOO datasets at a threshold of p ≤ 0.01 (Fig. 1) . A classifier based on the expression of the 58-transcript set was able to correctly discriminate all samples according to patient outcome (≥5-year disease-free versus metastasis), with the exception of one case (P598) (Fig. 1, right  panel) .
To evaluate the potential of this 58-transcript set to discriminate breast cancer patients according to the time required to develop metastasis, we generated a KM survival curve and this analysis showed significant discriminating power (p < 0.0001) in stratifying the patient samples according to time to develop metastasis (Fig. 2a) . For comparison, survival curves were generated based on Her2 and Ki67 expression statuses or the tumor histopathological grade, three currently used parameters to infer breast cancer outcome. It is apparent that the 58-gene set outperformed Her2 (p = 0.199) and Ki67 (p = 0.115) (Fig. 2b, c, respectively) and was comparable to the histopathological grade (p = 0.0082) (Fig. 2d) in discriminating patients according to their risk of developing metastasis. ROC curves were constructed to assess the individual potential of each gene from the metastasis signature to classify patients according to their disease outcomes. For each gene, the AUC was estimated to measure the sensitivity and specificity of the biomarker to correctly select the disease-free and metastatic cases. The AUC values ranged from 0.933 to 0.807 (Supplementary Table 7 ), suggesting good biomarker performance.
Biological network analysis
Enrichment analysis using two methods (IPA and KOBAS) identified pathways that are significantly over-represented (p < 0.05) among the 58-gene metastasis signature (Table 1) . These pathways included TRAF6-mediated NF-kB activation, the p53 pathway, toll-like receptor cascades (TLR5, TLR7/8, TLR6/2; TLR3/TLR4; TLR3; TLR2, TLR9, and TLR10), TRAF6-mediated induction of NF-kB and MAP Table 1) .
Validation of molecular markers of metastasis in breast cancer
To document the expression of the genes identified in the metastasis signature in independent datasets, the 58-gene signature was cross-referenced with the list of genes that are differentially expressed in metastatic breast cancer studies retrieved from the data collected and processed at the NCBI-GEO database (http://www.ncbi.nlm.nih.gov/geo/), which originated from 10 studies reported in the literature [11, 36 -45] . The cutoff values for selecting gene lists from each analysis were adjusted from p < 0.001 to p < 0.05 to retrieve a comparable number of genes in each analysis. In this metaanalysis, 12 transcripts were common. From this set, eight showed the same direction of transcriptional change that was observed in our study in 50 % or more of the studies used in the meta-analysis (Table 2) . Of note, only the GTSE1 and ZNF664 genes from our 58-gene signature showed overlapped with the genes present in the commercially available metastasis signature MammaPrint® [11] , and none of them was shared with the Oncotype DX® RT-qPCR-based signature [46] . Additionally, the ability of the 58-gene signature to predict patient outcome was evaluated in different publicly available breast cancer datasets [42, 47, ] . Using the SurvExpress multigene biomarker validation tool [33] , we found that the metastasis signature was very effective in discriminating patients at a higher risk of developing metastasis in the breast cancer datasets described by van de Vijver et al. [42] (n = 294; p = 4.1e −11 , HR = 5.2, 95 % CI 2.9-9.5; Fig. 3a) and by Kao et al. [47] (n = 367; p = 7.9e −8 , HR = 3.6, 95 % CI 2.2-6.0; Fig. 3b ). The metastasis signature also stratified these patients according to overall survival (p = 1.8e −9 , HR = 4.5, 95 % CI 2.6-7.7 and p = 6.7e −10 , HR = 4.6, 95 % CI 2.7-7.9, respectively) ( Supplementary Fig. 3a, b) . We note that no individual gene performed as well as the multigene signature to stratify BC patients according to time to metastasis and overall survival (data not shown). The potential of the 58-gene metastasis signature to predict disease outcome was further corroborated by its ability to discriminate patients according to their overall survival using the RNAseq gene expression data generated by the The Cancer Genome Atlas (TCGA) consortium from 502 BC patients [] (p = 3.2e −9 , HR = 5.2, 95 % CI 2.9-9.5; Supplementary Figure 3c) . We focused on a subset of genes from the metastasis signature (B3GNT7, PPM1D, TNKS2, PHB, and GTSE1), due to their importance in cell proliferation or because they are directly or indirectly involved in biological processes related to metastasis. Consistent with the oligoarray data, all five genes were significantly overexpressed (p < 0.05) in tumor samples from patients who developed metastasis compared to those that remained disease-free when the same samples (24-sample test set) were evaluated by RT-qPCR (Supplementary Figure 4, left panels) . More importantly, similar results were observed in an independent set of samples (validation set) comprising 47 primary tumor samples from patients who remained disease-free after surgery and eight primary tumor samples from patients who developed metastasis (Supplementary Figure 4, right panels) .
The BCL2-associated agonist of cell death (BAD) gene was downregulated in tumors from patients who developed metastasis (Supplementary Table 6 ). BAD protein expression was evaluated in a TMA comprising 1276 primary BC tissue samples from patients who developed metastasis (432 samples) or remained disease-free (370 samples) ( Table 3) . The tumors from patients who developed distant metastasis during the follow-up period exhibited lower expression levels of BAD (p < 0.0001). Reduced BAD expression was also statistically associated with positive lymph node status (p = 0.0035), negative ER status (p < 0.0001), negative PR status (p < 0.0001), negative Her2 status (p = 0.0182), more advanced pathological stages (p = 0.0002), and tumor size (T3-T4) (p = 0.0002). Interestingly, the percentage of cases with absent/low BAD expression (score 0) increased according to the number of lymph nodes involved. No statistically significant association was observed between BAD protein expression and age, family history, presence of distant metastasis at diagnosis, and histological grade (Table 3 ). In addition, the survival analysis showed that downregulation of BAD in primary tumors was significantly associated with SDFS (p = 0.0001, HR = 1.63; 95 % CI 1.23 to 2.15) and CSS (p < 0.0001, HR = 1.65; 95 % CI 1.25 to 2.18) (Fig. 4) . However, in the multivariate analyses, BAD expression was not statistically associated with SDFS or CSS (data not shown). Twelve genes that appeared in three or more studies were selected. Of these genes, eight had the same signal direction for the fold change in more than 50 % of studies in which expression values were measured. For each gene, the expression values are shown and refer to the log2 ratios between the metastatic and non-metastatic breast tumors a TCGA [45] b van't Veer et al. [11] c van de Vijver et al. [42] d Desmedt et al. [36] e Minn et al. [39] f Zhao et al. [44] g Karlsson et al. [38] h Wang et al. [43] i Sorlie et al. [41] j Molly et al. [40] k Jezequel et al. [37] Tumor Biol. (2016) 37:13855-13870
Discussion
In this study, a 58-gene expression signature associated with the clinical outcomes of BC in a cohort of Brazilian patients was identified, thus revealing new molecular markers with prognostic potential. The cross-referencing of this 58-gene set with the breast cancer prognosis signatures from 10 studies reported in the literature [11, [36] [37] [38] [39] [40] [41] [42] [43] [44] revealed 10 genes with concordant gene expression changes in at least one other analysis. Despite the discrepancies, this analysis reinforces the prognostic value of some genes, such as ITGAV, GTSE1, and AP2B, in breast cancer. Disagreement between gene signatures is frequently observed and may originate from individual variations, the molecular and clinical heterogeneity of tumors, the use of different platforms, and differences in patient selection, data normalization, methods of analysis, and other experimental choices [48] . In this regard, we observed a modest overlap with the genes present in the MammaPrint® signature and no overlap with the genes of the Oncotype Dx® signature. The 58-gene metastasis signature was further evaluated in three independent BC patient datasets with follow-up information. The metastasis gene set was able to stratify BC Fig. 3 Kaplan-Meier estimates of metastasis occurrence in patients with invasive breast cancer based on publicly available data using the metastasis signature to generate risk scores (see BMaterials and methods^for details). a Two hundred ninetyfour samples of primary breast carcinoma (data from [42] ). b Three hundred sixty-seven samples of breast carcinoma (data from [47] ). The log-rank test was used to ascertain the statistical significance of the differences between the survival curves patients according to high or low risk of disease-free survival or overall survival in all tested datasets. Altogether, these results provide independent indication of the robustness of the metastasis signature for risk stratification and highlight the value of this gene set as a resource to select candidates for biomarker development in BC.
The 58-gene set identified in this study was enriched in molecular pathways that may contribute to the metastatic dissemination of breast tumors. Noteworthy, the toll-like receptor (TLR) cascade pathway was represented by nine members of the TLR family (TLR5, TLR7/8, TLR6/2; TLR3/TLR4; TLR3; TLR2, TLR9, and TLR10). TLRs initiate a series of downstream signaling events that drive cellular responses, including the production of cytokines, chemokines, and other inflammatory mediators. In addition to driving inflammatory responses, TLRs also regulate cell proliferation and survival, which serves to expand useful immune cells and integrate inflammatory responses and tissue repair processes [49] . In colorectal cancer, TLR signaling may promote metastasis by activating the expression of integrins and chemokine receptors that facilitate tumor cell migration and the colonization of distal sites [50] . Several reports suggest that the TLR signaling pathway may play a supporting role in the secretion of proinflammatory cytokines/chemokines, aggressive tumor behavior (e.g., NF-κB activity), cell proliferation, cell invasion, cell migration, and metastasis in breast tumor cells [51] . Our study indicates that augmented TLR signaling is also a feature of metastatic breast tumors.
Genes associated with the p53 pathway were also overrepresented among the metastasis-associated gene set. The p53 protein directly controls the transcription of genes that are involved in canonical metastasis pathways, including cell adhesion, motility, invasion, EMT, stemness, and ECM interactions [52] . Eph-ephrin signaling genes were also identified in this signature. This family of molecules is involved in many aspects of both normal and carcinogenic developmental processes. In breast cancer, the roles of Eph receptors are extremely versatile and multifaceted, as they either promote or suppress tumor functions. The tumor-promoting effects seem to prevail [53] , which is in agreement with our findings.
Molecular pathways associated with BC invasiveness have also been identified. TRIP10, also known as Cdc42-interacting protein-4 (CIP4), was found upregulated in the tumors from patients who developed metastasis. Higher CIP4 levels have been shown to be significantly associated with a greater risk of metastatic progression in triplenegative breast cancer patients [54] . In addition to its value as a biomarker for patient outcome, it has been demonstrated that CIP4 localizes to cell invadopodia and positively contributes to cell invasion and metastasis in in vivo and in vitro breast cancer models, pointing to the functional relevance of this gene for metastatic dissemination in BC [54, 55] .
B3GNT7, PPM1D, TNKS2, PHB, and GTSE1 were significantly differentially expressed in the independent validation set. These genes were upregulated in the patients who Significant associations are in italics T tumor, N nodes, M metastasis, ER estrogen receptor alpha, PR progesterone receptor, Her2 human epidermal growth factor receptor 2 developed metastasis compared with those that remained disease-free. The B3GNT7 and PPM1D genes were previously associated with poor outcomes for breast cancer patients [56] ; however, the value of TNKS2, PHB, and GTSE1 genes as prognostic markers is currently unknown. B3GNT7 encodes an enzyme that is involved in a broad variety of biological functions that are mainly related to cell-cell communication [57] , differentiation [58] , and certain infectious diseases [59] , besides promoting cell motility and invasion in vitro [60] . The increased expression of B3GNT7 in metastatic cases compared to cases without metastasis indicates that this gene may be an important prognostic marker in breast cancer.
PPM1D is a hotspot for gene amplification in breast cancer [61] and has been detected in both breast cancer cell lines and primary breast tumors, which suggests its involvement in cancer development [56, 62] . PPM1D is involved in the regulation of several essential signaling pathways that are implicated in BC pathogenesis, such as the inhibition of tumor suppressor activities of TP53 [63] , p16INK4A, and p19ARF [64] and the activation of oncogenes, such as RAS, MYC, and NEU, thus promoting cellular transformation [65, 66] . In addition, PPM1D targets other key stress response kinases, such as ATM, CHK1, CHK2, and UNG2, which function in the DNA damage response and repair [63, 67] . These findings indicate that PPM1D is involved in the regulation of several essential signaling pathways that are implicated in breast cancer pathogenesis, and, therefore, it could be considered as a potential therapeutic target in patients with BC. Fig. 4 Systemic disease-free survival (SDFS, a) and cancerspecific KM survival (CSS, b) curves according to BAD protein status in breast tumor samples. p = 0.0001 for SDFS and p < 0.0001 for CSS were determined by the log-rank test TNKS2 (codified enzyme tankyrase, TRF1-interacting ankyrin-related ADP-ribose polymerase 2) positively regulates telomere length, and its expression has been detected in meningiomas and breast cancer [68] . The tumor suppressor gene PHB (prohibitin) encodes an anti-proliferative protein that functions by interacting with the Rb protein and its family members. Their putative association with the immunoglobulin (Ig)M receptor and estrogen receptor has suggested to have a possible role in cellular signaling, whereas the binding of prohibitin to E2F proteins has been taken as an indication of a possible role of PHB in transcriptional regulation during the cell cycle [69] . PHB is overexpressed in several carcinomas, and its role in tumorigenesis has been associated with the modulation of cell cycle control via Ras-Raf signaling, cell migration, mitochondrial physiology, and apoptosis [70, 71] . In this study, TNKS2 and PHB were upregulated in cases that presented metastasis in comparison to cases without metastasis in both the test and validation sets. Based on these results, we suggest that these genes may be potential prognostic markers of breast cancer.
GTSE1, which is present in the 58-gene metastasis signature, was also differentially expressed in patients with metastatic breast cancer, with the same signal direction as the TGCA analysis (2015). This gene (G2 and S phaseexpressed-1) plays a role in the G2 phase of the mitotic cell cycle. Its protein is co-localized with tubulin, suggesting that GTSE1 is associated with microtubules [72] . A physical interaction occurs between the C-terminal region of GTSE1 and the C-terminal regulatory domain of p53, which is necessary and sufficient to downregulate p53 activity. After DNA damage, GTSE1 could play a dual role during the G2 checkpoint, promoting a delay of the G2 to M transition and, at the same time, protecting these cells from p53-dependent apoptosis [73] . In one study, GTSE1 was found to be highly expressed in oral tongue squamous cell carcinoma samples and significantly associated with patients presenting lymph node metastasis [74] . To our knowledge, there are no previous studies associating the clinico-pathological significance of GTSE1 in patients with breast carcinoma.
We observed reduced expression of BAD in the tumors of patients who developed metastasis compared to patients who remained metastasis-free. We found significant associations between BAD downregulation and the occurrence of distant metastasis during the ≥5-year follow-up period (p < 0.0001), positive nodal status (p = 0.0035), negative ER status (p < 0.0001), negative PGR status (p < 0.0001), negative Her2 status (p = 0.0182), and tumor size (T3-T4) (p = 0.0002). In addition, the survival analysis showed that reduced BAD expression was statistically associated with shorter systemic disease-free survival (p = 0.001) and cancer-specific survival (p < 0.001). Cekanova et al. [75] suggest that, in addition to the effect on apoptosis, BAD conveys anti-metastatic effects and is a valuable prognostic marker of breast cancer. In line with this study, the gene and protein expression levels that were downregulated in our 58-gene set and protein analysis suggest that the expression level of BAD is a clinically relevant prognostic marker in breast carcinomas.
In conclusion, in this study, we identified a 58-gene expression signature that was able to distinguish patients according to their risk of developing metastasis more effectively than the clinico-pathological factors currently used for BC prognosis. This metastasis signature showed prognostic value in independent BC patient datasets. A subset of these genes was validated by transcript or protein expression analyses in an independent panel of samples, and the results highlighted candidates with the potential to stratify patients according to their risk of developing distant metastasis after diagnosis. Further studies with extended panels of patient samples are warranted to validate the clinical relevance of the novel biomarker candidates identified here.
